中国临床康复
中國臨床康複
중국림상강복
CHINESE JOURNAL OF CLINICAL REHABILITATION
2004年
13期
2494-2495
,共2页
李炜%王素娥%钟广伟%文玲波%邓干初
李煒%王素娥%鐘廣偉%文玲波%鄧榦初
리위%왕소아%종엄위%문령파%산간초
偏头痛/针灸疗法%针刺%P物质%神经肽Y%降钙索基因相关肽%内皮素%心钠素%神经降压肽
偏頭痛/針灸療法%針刺%P物質%神經肽Y%降鈣索基因相關肽%內皮素%心鈉素%神經降壓肽
편두통/침구요법%침자%P물질%신경태Y%강개색기인상관태%내피소%심납소%신경강압태
目的:探讨针刺治疗偏头痛对降钙素基因相关肽(calatonin gene-ralatedpeptide,CGRP)、P物质、内皮素、神经肽Y、心钠素、神经降压肽(neurotensin,NT)的影响.方法:将40只SD大鼠数字表法随机分为正常对照组、模型对照组、针刺对照组和针刺治疗组.按各组方案造模,或针刺治疗后,采用放射免疫法测定颈静脉血浆中多种神经肽的含量.结果:模型对照组CGRP(319.64±53.12)ng/L;P物质(126.76±39.29)ng/L;心钠素(366.11±83.12)ng/L;内皮素(785.00±186.64)ng/L;神经肽Y(4 567.06±1 041.86)ng/L均较正常对照组(152.87±31.82),(57.43+21.03),(278.31±58.76),(516.88±126.89),(3 232.75±424.87)ng/L有明显升高(t=2.283~2.791,P<0.05或0.01),而模型对照组NT(56.64±21.21)ng/L较正常对照组(113.12±35.92)ng/L明显降低(t=2.842,P<0.01);针刺治疗组CGRP(148.54±19.18)ng/L;P物质(60.76±22.31)ng/L;心钠素(287.63±68.64)ng/L;内皮素(524.38±122.55)ng/L;神经肽Y(3 324.56±576.77)ng/L均明显下降(t=2.833~2.481,P<0.05或P<0.01),NT(101.13±27.69)ng/L较模型对照组明显升高(t=2.669,P<0.05).结论:针刺调节脑神经肽的合成与释放,是其治疗偏头痛的主要因素之一.
目的:探討針刺治療偏頭痛對降鈣素基因相關肽(calatonin gene-ralatedpeptide,CGRP)、P物質、內皮素、神經肽Y、心鈉素、神經降壓肽(neurotensin,NT)的影響.方法:將40隻SD大鼠數字錶法隨機分為正常對照組、模型對照組、針刺對照組和針刺治療組.按各組方案造模,或針刺治療後,採用放射免疫法測定頸靜脈血漿中多種神經肽的含量.結果:模型對照組CGRP(319.64±53.12)ng/L;P物質(126.76±39.29)ng/L;心鈉素(366.11±83.12)ng/L;內皮素(785.00±186.64)ng/L;神經肽Y(4 567.06±1 041.86)ng/L均較正常對照組(152.87±31.82),(57.43+21.03),(278.31±58.76),(516.88±126.89),(3 232.75±424.87)ng/L有明顯升高(t=2.283~2.791,P<0.05或0.01),而模型對照組NT(56.64±21.21)ng/L較正常對照組(113.12±35.92)ng/L明顯降低(t=2.842,P<0.01);針刺治療組CGRP(148.54±19.18)ng/L;P物質(60.76±22.31)ng/L;心鈉素(287.63±68.64)ng/L;內皮素(524.38±122.55)ng/L;神經肽Y(3 324.56±576.77)ng/L均明顯下降(t=2.833~2.481,P<0.05或P<0.01),NT(101.13±27.69)ng/L較模型對照組明顯升高(t=2.669,P<0.05).結論:針刺調節腦神經肽的閤成與釋放,是其治療偏頭痛的主要因素之一.
목적:탐토침자치료편두통대강개소기인상관태(calatonin gene-ralatedpeptide,CGRP)、P물질、내피소、신경태Y、심납소、신경강압태(neurotensin,NT)적영향.방법:장40지SD대서수자표법수궤분위정상대조조、모형대조조、침자대조조화침자치료조.안각조방안조모,혹침자치료후,채용방사면역법측정경정맥혈장중다충신경태적함량.결과:모형대조조CGRP(319.64±53.12)ng/L;P물질(126.76±39.29)ng/L;심납소(366.11±83.12)ng/L;내피소(785.00±186.64)ng/L;신경태Y(4 567.06±1 041.86)ng/L균교정상대조조(152.87±31.82),(57.43+21.03),(278.31±58.76),(516.88±126.89),(3 232.75±424.87)ng/L유명현승고(t=2.283~2.791,P<0.05혹0.01),이모형대조조NT(56.64±21.21)ng/L교정상대조조(113.12±35.92)ng/L명현강저(t=2.842,P<0.01);침자치료조CGRP(148.54±19.18)ng/L;P물질(60.76±22.31)ng/L;심납소(287.63±68.64)ng/L;내피소(524.38±122.55)ng/L;신경태Y(3 324.56±576.77)ng/L균명현하강(t=2.833~2.481,P<0.05혹P<0.01),NT(101.13±27.69)ng/L교모형대조조명현승고(t=2.669,P<0.05).결론:침자조절뇌신경태적합성여석방,시기치료편두통적주요인소지일.